Oncotelic Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
29397 Agoura Rd Ste 107, Agoura Hills, C...Phone Number
(650) 635-7000Website
www.oncotelic.comRevenue
<$5 MillionStock Symbol
OTLCIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Oncotelic Therapeutics
Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Mateon has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503).Explore more
Oncotelic Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncotelic Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Oncotelic Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Oncotelic Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Oncotelic Therapeutics
Oncotelic Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Oncotelic Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Oncotelic Therapeutics recently announced quarterly report
Product Launch: Get notified when Oncotelic Therapeutics launches new products
Click to see if Oncotelic Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Oncotelic Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Oncotelic Therapeutics
Compare insights from companies similar to Oncotelic Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Oncotelic Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oncotelic Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncotelic Therapeutics.
Oncotelic Therapeutics financials insights
Gather financial insights about Oncotelic Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$10.1M
2026
Stock/Share Issuance
$712K
Oncotelic Therapeutics Tech Stack
A closer look at the technologies used by Oncotelic Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Person-Based
Medical Research, Pharmaceuticals
Hiring Plans
Oncotelic Therapeutics has more open roles in Operations than it has had at any time in the past 12 months. Areas of expertise include: Supply Chain, Corrective Action Management, Warehouse Management, and Key Performance Indicators (KPIs).
Hiring Plans
Hiring Plans
Oncotelic Therapeutics has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
New Hire
Executive Move
Oncotelic Therapeutics News & Media
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
AGOURA HILLS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in Biomedicines describing the preclinical translational package supporting Sapu003, the Company's intravenous Deciparticle™ formulation of everolimus. The publication provides a complete evaluation of the formulation's absorption, distribution, metabolism, excretion (ADME), pharmacokinetics (PK), tissue distributiOncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle™ PlatformOncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle™ Technology for Hydrophobic TherapeuticsOncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical Manufacturing
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Oncotelic Therapeutics
Sign Up For FreeTo access detailed company insights
Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer... Read More
